📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-01 09:45
466 analysed today
FollowTelegram
466
Today
150,417
All-time analysed
43,082
Positive
6,691
Negative
91,895
Neutral
8,681
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Zydus Wellness Appoints Ex-P&G Leader Kapil Sharma as Chief Revenue Officer
Zydus Wellness Limited has appointed Mr. Kapil Sharma as Chief Revenue Officer (India and Indian subcontinent), effective September 1, 2026. Mr. Sharma brings over 28 years of commercial and sales experience, including 25 years at Procter & Gamble (P&G), where he recently served as VP-Gillette for the subcontinent. The appointment comes as the company seeks to expand its direct retail distribution reach to 3.5 million outlets and scale its ₹1,947 Cr TTM revenue base.
Confidence: HIGH
What changedMr. Kapil Sharma has taken charge as Chief Revenue Officer (India & Indian subcontinent) as part of Zydus Wellness's Senior Management.
Why it mattersAdds high-caliber consumer goods leadership to steer domestic sales, direct-to-consumer strategy, and distribution growth across key brands like Complan, Glucon-D, and Nycil.
Effective Date: September 1, 2026Total Professional Experience: 28+ yearsP&G Tenure: 25 yearsTTM Revenue Base: ₹1947 Cr
📅 Short termOperational transition with no immediate financial impact; positive sentiment for strengthening commercial leadership.
📈 Long termSupports the company's long-term target of widening direct distribution reach and improving product monetization across seasonal and non-seasonal portfolios.
⚠ Risk flags
- Execution risk in competitive FMCG health food drinks and personal care categories
Key Highlights
Appointed Mr. Kapil Sharma as Chief Revenue Officer (India and Indian subcontinent) effective September 1, 2026.
Mr. Sharma brings 28+ years of sales and commercial leadership experience, including 25 years at P&G.
Previously served as VP-Gillette for India and subcontinent, leading brands such as Gillette, Venus, and Braun.
Brings specialized background in digital commerce, retail transformation, and profitability turnarounds across India and Asia.
👀 What to Watch
Monitor upcoming quarterly revenue execution, distribution footprint expansion, and strategies to address the company's seasonal revenue skew.
66.7% Revenue Growth in Q1 FY27; Digital Sales Reach 21% Saliency
Zydus Wellness reported a significant 66.7% YoY increase in consolidated net sales to ₹1,429.9 cr for Q1 FY27, primarily driven by the integration of the Comfort Click acquisition. While the international business grew 24.8% like-for-like, domestic growth was a modest 4.6% as seasonal brands (Nycil, Glucon-D) declined by 12% due to unseasonal rainfall. EBITDA rose 55.3% to ₹241.7 cr, although reported net profit fell 7% due to brand amortization costs. The company is successfully pivoting to digital channels, with digital commerce now accounting for 21% of total sales.
Confidence: HIGH
What changedThe company has significantly scaled its international and digital footprint, reducing its historical 70% revenue dependency on the Indian summer season.
Why it mattersThe massive revenue jump validates the Comfort Click acquisition strategy, while the 21% digital saliency indicates a successful shift toward premium, high-growth distribution channels.
Q1 FY27 Net Sales: ₹1,429.9 crYoY Revenue Growth: 66.7%EBITDA Growth: 55.3%Digital Commerce Saliency: 21%A&P Spend as % of Sales: 18.2%Domestic Business Growth: 4.6%
📅 Short termThe strong top-line and EBITDA growth are likely to be viewed positively, though the reported PAT decline due to amortization may require investor education on cash vs. accounting profits.
📈 Long termThe structural shift toward a diversified, digital-first portfolio reduces seasonal volatility and improves the long-term margin profile through premiumization.
⚠ Risk flags
- High seasonality risk (weather-sensitive brands)
- Brand amortization impacting reported net profit
- Intense competition in the Health Food Drink (Complan) segment
Key Highlights
Consolidated net sales grew 66.7% YoY to ₹1,429.9 cr, representing ~76% of previous TTM revenue in a single quarter.
International business delivered 24.8% like-for-like growth, supported by expansion into U.S. and Middle East markets.
Digital commerce saliency reached 21%, contributing to a total organized channel share of 38%.
EBITDA increased 55.3% YoY to ₹241.7 cr, with margins expanding by 0.4% on a like-for-like basis.
Seasonal brands declined by 12% due to frequent summer showers in North and East India, impacting Nycil and Glucon-D.
👀 What to Watch
Monitor the performance of seasonal brands in the next summer cycle and the continued margin contribution from the Comfort Click acquisition. Investors should focus on 'Cash PAT' (up 26.5%) rather than reported PAT to account for non-cash brand amortization.
66.7% Net Sales Growth in Q1 FY27; EBITDA up 55.3% to ₹241.7 Cr
Zydus Wellness reported a strong Q1 FY27 with consolidated net sales reaching ₹1,429.9 Cr, a 66.7% increase from ₹857.7 Cr in the previous year. EBITDA grew by 55.3% to ₹241.7 Cr, while net profit for the quarter stood at ₹118.9 Cr. The company maintained dominant market leadership in key categories, including a 96.1% share in sugar substitutes and 59.1% in energy drinks. Strategic expansions included entering the Walmart Marketplace in the USA and launching new products like Complan Power Play and VieMax Diabetes Care.
Confidence: HIGH
What changedThe company delivered a significant YoY jump in revenue and EBITDA, driven by market share gains and the integration of new brands like Comfort Click.
Why it mattersQ1 is the most critical quarter for Zydus Wellness due to the high seasonality of Glucon-D and Nycil; this strong performance provides a solid base for FY27 growth targets.
Net Sales (Q1 FY27): ₹1,429.9 CrYoY Sales Growth: 66.7%EBITDA: ₹241.7 CrNet Profit: ₹118.9 CrSugar Free Market Share: 96.1%Q1 Revenue vs TTM Revenue: 76.01%
📅 Short termThe stock is likely to react positively to the high double-digit revenue and EBITDA growth, confirming strong execution during the peak summer season.
📈 Long termThe long-term outlook depends on the company's ability to scale Complan and new nutrition launches to balance its seasonal revenue skew and improve its ROCE from the current 2%.
⚠ Risk flags
- High seasonality (70% revenue from summer products)
- Intense competition in the Health Food Drink segment
- Low historical ROCE of 2.0%
Key Highlights
Net Sales grew 66.7% YoY to ₹1,429.9 Cr for the quarter ended June 30, 2026.
EBITDA increased by 55.3% YoY to ₹241.7 Cr.
Sugar Free maintained a near-monopoly market share of 96.1% in its category.
Everyuth Peel-off category market share reached 75.5%, while Glucon-D held 59.1%.
International expansion progressed with WeightWorld entering the Walmart Marketplace in the USA.
👀 What to Watch
Investors should monitor the performance of new launches in the diabetes care and ready-to-drink segments to see if they can reduce the company's 70% revenue dependence on the summer season. Watch for the impact of international DTC expansion on overall margins in upcoming quarters.
66.7% Revenue Growth in Q1 FY27; Adjusted PAT up 26.5% Following Comfort Click Integration
Zydus Wellness reported a sharp 66.7% YoY increase in Net Sales to ₹1,429.9 crore for Q1 FY27, primarily driven by the consolidation of the Comfort Click acquisition. While reported PAT declined 7% to ₹118.9 crore due to a 920% surge in brand amortization (₹49 crore), adjusted net profit grew 26.5% to ₹167.9 crore. The core portfolio remains dominant with Sugar Free holding a 96.1% market share, though seasonal brands like Glucon-D saw flattish growth due to unseasonal rains in North and East India.
Confidence: HIGH
What changedThe company has successfully consolidated the Comfort Click acquisition, leading to a step-change in revenue scale and a significant increase in non-cash amortization expenses.
Why it mattersThe acquisition significantly expands Zydus Wellness's international footprint and digital presence, though the high amortization will continue to weigh on reported PAT while adjusted cash profits remain healthy.
Q1 FY27 Net Sales: ₹1,429.9 crQ1 Sales vs TTM Revenue: 76.01%Adjusted Net Profit Growth: 26.5%Sugar Free Market Share: 96.1%Amortization Expense (Q1): ₹49.0 cr
📅 Short termThe market is likely to react positively to the massive top-line growth and adjusted profit expansion, despite the accounting-led dip in reported PAT.
📈 Long termThe shift towards a more diversified, less seasonal portfolio through acquisitions is structurally positive, though improving the low ROCE (2.0%) remains a long-term challenge.
⚠ Risk flags
- High seasonality (70% revenue skew towards summer months)
- Significant non-cash amortization impacting reported earnings
- Low ROCE relative to FMCG peers
Key Highlights
Net Sales surged 66.7% YoY to ₹1,429.9 crore, representing ~76% of previous TTM revenue in a single quarter.
Adjusted Net Profit (excluding brand amortization) grew 26.5% YoY to ₹1,67.9 crore.
Sugar Free maintains a dominant 96.1% market share, with the 'Green' variant delivering its 21st consecutive quarter of double-digit growth.
Everyuth Scrub market share increased by 65.9 bps YoY to reach 49.4%, moving the brand to 4th rank in the facial cleansing category.
Amortization of acquired brands increased significantly to ₹49 crore from ₹4.8 crore in the previous year.
👀 What to Watch
Watch for the stabilization of margins as the Comfort Click acquisition integrates and monitor if the company can sustain double-digit growth in the 'Sugar Free' and 'Everyuth' segments to offset seasonality in Glucon-D.
Zydus Wellness Q1 Standalone Revenue Up 8.6% YoY to ₹153 Cr; Net Profit at ₹5.5 Cr
Zydus Wellness reported standalone revenue of ₹153 crore for Q1 FY27 (ended June 30, 2026), marking an 8.6% growth over the ₹140.9 crore reported in the same quarter last year. Standalone net profit rose 19.6% YoY to ₹5.5 crore, although it saw a sequential decline from the ₹13.3 crore earned in the March 2026 quarter. The results highlight the company's extreme seasonality, with performance heavily dependent on summer-centric brands. The standalone business represents approximately 31% of the group's TTM consolidated revenue, with the remainder driven by subsidiaries including the recently acquired Comfort Click Limited.
Confidence: HIGH
What changedThe company released its unaudited standalone and consolidated financial results for the first quarter of the 2026-27 fiscal year, showing modest growth in its standalone operations.
Why it mattersQ1 is a seasonally significant period for Zydus Wellness due to its summer-heavy product mix (Glucon-D, Nycil); these results provide an early indicator of the year's performance trajectory and the health of its standalone consumer business.
Standalone Revenue (Q1): 1,530 MillionStandalone Net Profit (Q1): 55 MillionMaterial Cost as % of Revenue: 66.7%Comfort Click Acquisition Cost: GBP 239 millionStandalone Q1 Revenue vs TTM Consolidated Revenue: ~8.1%
📅 Short termThe stock is likely to remain neutral in the short term as the standalone growth is modest and the market awaits full consolidated details on the international business integration.
📈 Long termLong-term value depends on the successful integration of international acquisitions and the ability to scale non-seasonal brands like RiteBite and Complan to balance the revenue skew.
⚠ Risk flags
- High seasonality (70% revenue in summer months)
- High raw material cost concentration (66.7% of standalone revenue)
- Integration risks associated with the large GBP 239 million UK acquisition
Key Highlights
Standalone Revenue from operations grew to ₹153 crore (1,530 million) from ₹140.9 crore YoY.
Standalone Net Profit increased to ₹5.5 crore (55 million) compared to ₹4.6 crore in the year-ago period.
Cost of materials consumed rose significantly to ₹102.1 crore, representing 66.7% of revenue.
Acquisition of Comfort Click Limited (UK) was completed for GBP 239 million plus a GBP 2.64 million profit-ticker.
The company implemented a stock split from face value ₹10 to ₹2 on September 19, 2025.
👀 What to Watch
Investors should monitor the consolidated financial performance to gauge the full impact of the Comfort Click acquisition and track the company's progress in reducing its 70% revenue dependency on the summer season.
Zydus Wellness Appoints Dr. Shyam Ramakrishnan as Chief Scientific Officer Effective July 1, 2026
Zydus Wellness has appointed Dr. Shyam Ramakrishnan as Chief Scientific Officer (CSO) and part of the Senior Management, effective July 1, 2026. Dr. Ramakrishnan brings over 25 years of experience in nutrition, dietary supplements, and functional foods, having held leadership roles at Amway, ITC, and The Himalaya Drug Company. This strategic hire is significant as the company seeks to diversify its portfolio beyond its current 70% revenue dependency on seasonal summer products like Glucon-D and Nycil. With a TTM revenue of ₹1,881 Cr and a high P/E of 70.8, the market will look for R&D-led innovation to drive growth and improve the current 2.0% ROCE.
Confidence: HIGH
What changedZydus Wellness has added a high-profile Chief Scientific Officer to its senior management team to lead innovation and R&D.
Why it mattersThe company needs to innovate to justify its high valuation (70.8 P/E) and to balance its portfolio, which currently relies on seasonal products for 70% of its annual revenue.
Experience of Appointee: 25+ yearsTTM Revenue: ₹1881 CrRevenue Seasonality: 70% (Jan-June)Market Cap: ₹13353 CrROCE: 2.0%
📅 Short termThe announcement is unlikely to impact the stock price immediately as the appointment is effective from July 2026, but it signals a long-term commitment to R&D.
📈 Long termCrucial for structural growth; a strong R&D head can help the company transition into a year-round wellness player and improve low capital efficiency (2.0% ROCE).
⚠ Risk flags
- Execution risk in new product categories
- High revenue concentration in summer months (70%)
Key Highlights
Appointment of Dr. Shyam Ramakrishnan as Chief Scientific Officer effective July 1, 2026
Appointee brings over 25 years of experience across nutrition, personal care, and functional foods
Previous leadership experience includes roles at Hill’s Pet Nutrition, The Himalaya Drug Company, ITC Ltd., and Amway
The role focuses on translational science, clinical research, and innovation platform development
Company is currently managing a 70% revenue skew towards the summer season (January to June)
👀 What to Watch
Monitor the company's R&D pipeline and the launch of new functional food variants over the next 4-6 quarters to see if the new leadership can effectively reduce seasonal revenue volatility.
Zydus Wellness Incorporates New Step-Down Subsidiary in Dubai for UAE Expansion
Zydus Wellness Limited has announced the incorporation of a new step-down wholly owned subsidiary, Zydus Wellness Trading L.L.C. (ZWTL), in Dubai, UAE. The entity was formed through its subsidiary Zydus Wellness International DMCC with a share capital of AED 300,000. This move is aimed at expanding the company's international footprint in the Food and Nutrition, Nutraceuticals, and Personal Care segments. While the entity has nil turnover currently, it represents a strategic move to capture market share in the Middle East.
Key Highlights
Incorporation of Zydus Wellness Trading L.L.C. (ZWTL) as a 100% step-down subsidiary in Dubai.
Initial share capital of AED 300,000 divided into 300 shares of AED 1,000 each.
Focus sectors include Food and Nutrition, Nutraceuticals, and Personal Care products.
The subsidiary is a 100% owned entity of Zydus Wellness International DMCC, UAE.
The move is specifically designated for business expansion in the UAE market.
👀 What to Watch
Investors should view this as a positive long-term strategic step to diversify geographic revenue; monitor future quarterly reports for updates on international revenue contribution.
Zydus Wellness Incorporates Step-Down Subsidiary in Ireland for VMS Expansion
Zydus Wellness has announced the incorporation of a new step-down wholly owned subsidiary, Zydus Wellness (EU) Limited, in Ireland. The entity was established through the company's UAE-based subsidiary, Zydus Wellness International DMCC, which holds 100% of the share capital. This move is aimed at business expansion within the Vitamins, Minerals, and Supplements (VMS) industry. While the initial capital is nominal at €100, it marks a strategic entry into the European market.
Key Highlights
Incorporation of Zydus Wellness (EU) Limited in Ireland on June 23, 2026
100% ownership held by UAE-based subsidiary Zydus Wellness International DMCC
Initial share capital of €100 consisting of 100 ordinary shares of €1 each
Focus on the Vitamins, Minerals and Supplements (VMS) business segment
Entity is a newly incorporated unit with operations yet to commence
👀 What to Watch
Investors should view this as a long-term strategic move to capture the European VMS market. Monitor future quarterly updates for capital allocation and revenue contributions from this new geography.
Zydus Wellness Q4 FY26: Net Sales Surge 62.1% Driven by International Growth and Acquisitions
Zydus Wellness reported a robust 62.1% growth in net sales for Q4 FY26, primarily fueled by the international business and the Comfort Click acquisition. While the domestic business saw a modest 1.7% growth, skin and hair care brands outperformed with a 39.7% increase. EBITDA grew by 42.2% to INR 2,701 million, although reported net profit declined due to acquisition-related finance costs and amortization. Adjusted net profit, excluding exceptional items, showed a healthy 17% growth for the quarter.
Key Highlights
Net sales grew 62.1% YoY in Q4 FY26, with full-year EBITDA reaching INR 5,097 million.
International business delivered 31.4% like-to-like growth, while domestic seasonal brands declined 9.8% due to unseasonal rains.
Organized channel saliency (E-commerce and Modern Trade) improved to 30% from 24% in the previous year.
Sugar Free market share expanded by 24 basis points, and Sugar Free Green recorded its 20th consecutive quarter of double-digit growth.
Adjusted net profit (excluding amortization and exceptional items) grew 17% YoY for the quarter.
👀 What to Watch
Investors should monitor the recovery of high-margin seasonal brands like Glucon-D in the upcoming quarters and the stabilization of finance costs following the recent acquisition. The strong growth in the international segment and digital-first brands provides a positive long-term outlook despite short-term domestic headwinds.
Zydus Wellness Recommends ₹1.20 Dividend; Sets Record Date for July 17, 2026
Zydus Wellness has recommended a final dividend of ₹1.20 per equity share (60% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine eligible shareholders, with payments starting from August 7, 2026. Additionally, the board has appointed Mr. Apurva S. Diwanji, a legal and M&A veteran, as an Independent Director for a five-year term. The 32nd Annual General Meeting is scheduled for August 4, 2026, to seek shareholder approval for these proposals.
Key Highlights
Recommended final dividend of ₹1.20 per share (60% of ₹2 face value)
Record date for dividend entitlement is fixed as July 17, 2026
Appointment of Mr. Apurva S. Diwanji as Independent Director for a 5-year term
Dividend payment to commence on or after August 7, 2026, post-AGM approval
32nd Annual General Meeting scheduled for August 4, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the July 17 record date. The addition of a legal and M&A expert to the board is a positive step for corporate governance and strategic oversight.
Zydus Wellness Q4 Net Sales Surges 62.1% to Rs 14,761 Million; FY26 Sales Up 46.4%
Zydus Wellness reported a robust performance for Q4 FY26 with net sales growing 62.1% YoY to Rs 14,761 million, while annual sales reached Rs 39,400 million. The company's EBITDA grew by 34.2% to Rs 5,097 million, reflecting the successful integration of its newly acquired business and strong organic growth. Key brands like Sugar Free and Glucon-D maintained dominant market shares of 96.1% and 58.9% respectively. The RiteBite Max Protein business showed significant margin improvement, moving from breakeven to near double-digit margins within a year of acquisition.
Key Highlights
Net Sales for Q4 FY26 grew by 62.1% YoY to Rs 14,761 million, while FY26 sales rose 46.4% to Rs 39,400 million.
EBITDA for the period stood at Rs 5,097 million, marking a 34.2% YoY growth including post-acquisition performance.
Sugar Free maintains a near-monopoly with 96.1% market share, while Glucon-D leads the category with 58.9% share.
RiteBite Max Protein business improved from breakeven at acquisition to near double-digit EBITDA margins.
Everyuth leads the scrub category with 48.6% share and peel-off masks with 75.5% share, delivering strong double-digit growth.
👀 What to Watch
Investors should note the strong top-line momentum and the successful margin expansion in the recently acquired protein business. The company's dominant market share across multiple wellness categories makes it a strong play in the FMCG-Healthcare hybrid space.
Zydus Wellness Q4 FY26: Sugar Free Hits 96.1% Market Share; Complan Shows Recovery
Zydus Wellness demonstrated strong market dominance in Q4 FY26, with its flagship brand Sugar Free maintaining a 96.1% market share. The company reported a significant recovery in Complan, which achieved near double-digit growth despite a 4.8% decline in the overall category. Strategic expansion into the protein snacking segment via Max Protein is yielding results, with the brand reaching nearly double-digit EBITDA margins. Additionally, the company strengthened its balance sheet by repurchasing ₹15,000 million in NCDs following a ₹10,000 million capital raise.
Key Highlights
Sugar Free maintains a dominant 96.1% market share, with Sugar Free Green delivering 20 consecutive quarters of double-digit growth.
Complan outperformed its category by growing near double-digits while the broader market segment declined by 4.8%.
Everyuth brand reached an 8.0% share in facial cleansing, ranking 4th in the JFM'26 quarter, with leadership in scrubs (48.6%) and peel-off masks (75.5%).
Max Protein portfolio successfully transitioned from break-even to nearly double-digit EBITDA margins due to operating leverage.
Completed a ₹10,000 million capital restructure and repurchased ₹15,000 million of NCDs to optimize the balance sheet.
👀 What to Watch
Investors should monitor the sustained recovery in Complan and the scaling of the Max Protein segment as primary growth catalysts. The company's ability to maintain near-monopoly shares in core categories while reducing debt makes it a strong play in the FMCG wellness space.
Zydus Wellness Recommends ₹1.20 Dividend and Appoints Apurva Diwanji as Independent Director
Zydus Wellness has recommended a final dividend of ₹1.20 per equity share (60% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine eligibility for the dividend payment, which is expected to commence on or after August 7, 2026. Additionally, the board has appointed Mr. Apurva S. Diwanji as an Independent Director for a five-year term. Mr. Diwanji is a legal veteran with over 32 years of experience in M&A and corporate governance, having previously served on the board of Zydus Lifesciences.
Key Highlights
Recommended a final dividend of ₹1.20 per equity share of ₹2 each (60% payout).
Fixed July 17, 2026, as the record date for dividend entitlement.
Appointed Mr. Apurva S. Diwanji as an Independent Director for a 5-year term until May 2031.
Mr. Diwanji brings 32+ years of expertise in M&A, private equity, and corporate law.
The 32nd Annual General Meeting is scheduled for August 4, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the July 17 record date. The addition of a seasoned legal and M&A expert to the board is a positive signal for corporate governance and strategic oversight.
Zydus Wellness Recommends Final Dividend of ₹1.20 Per Share for FY26
Zydus Wellness Limited has recommended a final dividend of ₹1.20 per equity share for the financial year ended March 31, 2026. This represents a 60% payout on the face value of ₹2 per share. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for August 4, 2026. The company also confirmed that its statutory auditors have issued an unmodified opinion on the audited financial results for the year.
Key Highlights
Recommended a final dividend of ₹1.20 per equity share of ₹2 face value
Dividend payout represents 60% of the face value of the shares
Annual General Meeting for dividend approval is scheduled for August 4, 2026
Statutory auditors Mukesh M. Shah & Co. submitted an unmodified audit report for FY26
👀 What to Watch
Investors interested in the dividend yield should monitor for the announcement of the record date. The recommendation reflects the company's commitment to returning value to shareholders following the completion of the fiscal year.
Zydus Wellness Q4 FY26 Results: Board Recommends Final Dividend of ₹1.20 Per Share
Zydus Wellness has approved its audited financial results for the quarter and full year ended March 31, 2026. The Board recommended a final dividend of ₹1.20 per equity share, which is 60% of the face value of ₹2. The statutory auditors issued an unmodified opinion on the financial statements, ensuring reporting transparency. The dividend is subject to shareholder approval at the upcoming Annual General Meeting on August 4, 2026.
Key Highlights
Recommended a final dividend of ₹1.20 per equity share (60% of ₹2 face value).
Statutory auditors Mukesh M. Shah & Co. provided an unmodified opinion for FY26 results.
Annual General Meeting (AGM) for shareholders scheduled for August 4, 2026.
Trading window for designated persons to reopen on May 21, 2026.
👀 What to Watch
Investors should review the detailed profit and loss statements for revenue growth and margin trends once the full report is analyzed. The dividend provides a modest yield, so the focus should remain on the company's growth trajectory in the wellness segment.
Zydus Wellness Q3 Net Sales Surge 113.7% to ₹9,633 Mn Driven by Comfort Click Acquisition
Zydus Wellness reported a massive 113.7% YoY increase in Q3 FY26 Net Sales to ₹9,633 million, primarily driven by the strategic acquisition of Comfort Click. While Gross Margins expanded significantly by 1561 bps to 63.3%, the company reported a PAT loss of ₹399 million for the quarter due to high finance costs of ₹371 million and brand amortization of ₹472 million related to the acquisition. Core brands like Sugar Free and Glucon-D continue to maintain dominant market leadership with 96.3% and 59% shares respectively, while the RiteBite business has doubled its legacy performance.
Key Highlights
Q3 FY26 Net Sales grew 113.7% YoY to ₹9,633 million; YTD FY26 sales reached ₹24,639 million.
Gross Margin for Q3 FY26 improved by 1561 bps YoY to 63.3%, supported by newly acquired high-margin brands.
Reported a Q3 PAT loss of ₹399 million, impacted by acquisition-related interest and non-cash amortization expenses.
Sugar Free maintains a dominant 96.3% market share, while Everyuth Peel-off leads its category with 76% share.
Distribution network expanded to 2.8 million total stores with a direct reach of 0.7 million outlets.
👀 What to Watch
Investors should look past the headline PAT loss which is skewed by one-time acquisition costs and non-cash amortization; focus instead on the robust EBITDA growth and massive gross margin expansion. Monitor the company's ability to deleverage the bridge loan used for the acquisition to improve bottom-line profitability in coming quarters.
Zydus Wellness Q3 FY26 Sales Grow 113.7% to ₹9,633 Mn; Gross Margins Expand 1561 Bps
Zydus Wellness reported a massive 113.7% YoY increase in Q3 FY26 net sales to ₹9,633 million, primarily driven by the integration of the newly acquired Comfort Click and RiteBite businesses. Gross margins saw a significant expansion of 1561 bps to 63.3%, although the company reported a net loss of ₹399 million for the quarter due to high finance costs and amortization related to acquisitions. The company maintains dominant market leadership in core categories, with Sugar Free holding a 96.3% share and Glucon-D at 59.0%. Strategic capital restructuring was completed with a ₹10,000 million fundraise and ₹15,000 million NCD repurchase to optimize the balance sheet.
Key Highlights
Net Sales for Q3 FY26 surged 113.7% YoY to ₹9,633 million, while YTD FY26 sales grew 38.4% to ₹24,639 million.
Gross Margin expanded to 63.3% in Q3 FY26, up from 47.7% in the previous year, supported by new high-margin brands.
Sugar Free remains the market leader with a 96.3% share, while Everyuth Peel-off and Scrub hold 76.0% and 48.5% shares respectively.
EBITDA for Q3 FY26 grew by 312.2% YoY to ₹610 million, despite bottom-line pressure from ₹371 million in finance costs.
Completed acquisition of Comfort Click Limited, adding international brands like WeightWorld and maxmedix to the portfolio.
👀 What to Watch
Investors should focus on the company's ability to transition the high revenue growth into net profitability as acquisition-related interest and amortization costs stabilize. The strong market share in core brands provides a solid foundation, but the performance of the international VMS segment will be the primary driver for future re-rating.
Zydus Wellness Q3 FY26 Net Sales Surge 113.7% Driven by Comfort Click Acquisition
Zydus Wellness reported a massive 113.7% YoY increase in net sales for Q3 FY26, primarily fueled by the integration of the Comfort Click acquisition. While the company reported a net loss of INR 399 million due to high amortization and interest costs from the acquisition, EBITDA grew by 312.2% to INR 610 million. Gross margins expanded significantly to 63% as the new business operates at higher margins, with management targeting 66-67% on an annualized basis. The RiteBite business also showed strong momentum, doubling its legacy performance and nearing double-digit EBITDA margins.
Key Highlights
Net sales grew 113.7% YoY, with the Food & Nutrition segment surging 134%
EBITDA increased by 312.2% YoY to INR 610 million, with margins expanding to 6.3%
Gross margins reached 63% due to the high-margin Comfort Click portfolio mix
Reported a net loss of INR 399 million after accounting for INR 472 million in brand amortization and INR 371 million in interest
RiteBite Max Protein business doubled its legacy performance and is approaching double-digit margins
👀 What to Watch
Investors should focus on the strong operational growth and margin expansion post-acquisition, while monitoring the deleveraging process and the impact of non-cash amortization on reported profits.
Zydus Wellness Q3 FY26 Net Sales Surge 113.7% to Rs 9,633 Mn; EBITDA Jumps 312%
Zydus Wellness reported a massive 113.7% year-on-year growth in net sales for Q3 FY26, reaching Rs 9,633 million, largely driven by the integration of newly acquired businesses. EBITDA saw an even more significant jump of 312.2% to Rs 610 million, reflecting improved operational efficiency and margin expansion in brands like RiteBite. The company maintained dominant market leadership in key categories, including Sugar Free with a 96.3% share and Glucon-D with a 59% share. Furthermore, the expansion of the 'WeightWorld' brand into European markets like Poland and Finland signals a strong international growth strategy.
Key Highlights
Net Sales grew by 113.7% y-o-y to Rs 9,633 million, while EBITDA rose 312.2% to Rs 610 million.
Sugar Free maintained a dominant 96.3% market share, gaining 80 basis points year-on-year.
RiteBite Max Protein margins improved from breakeven a year ago to near double-digit levels.
Glucon-D and Nycil retained leadership positions with 59% and 33.1% market shares respectively.
International expansion continued with Comfort Click entering Poland, Finland, and Portugal.
👀 What to Watch
Investors should view the strong sales and EBITDA growth as a sign of successful acquisition integration and brand strength. Monitor the sustainability of margins in the newly acquired segments and the performance of international expansions.
Zydus Wellness Q3 FY26 Net Sales Surge 113.7% to ₹963 Cr; Gross Margins Expand 1561 bps
Zydus Wellness reported a massive 113.7% YoY increase in net sales to ₹963.3 crore for Q3 FY26, primarily driven by the integration of Comfort Click and strong momentum in the RiteBite Max Protein business. Gross margins saw a significant expansion of 1561 bps to 63.3%, aided by a favorable product mix and newly acquired international brands. Despite the top-line surge, the company reported a PAT loss of ₹39.9 crore for the quarter, compared to a profit of ₹6.4 crore in the previous year, reflecting acquisition-related impacts. Core brands like Sugar Free and Everyuth maintained dominant market leadership with 96.3% and 48.5% shares respectively.
Key Highlights
Net Sales for Q3 FY26 grew by 113.7% YoY to ₹9,633 million, while YTD FY26 sales rose 38.4% to ₹24,639 million.
Gross Margin expanded significantly by 1561 bps YoY to 63.3% in Q3 FY26, driven by premiumization and the Alidac UK acquisition.
RiteBite Max Protein business doubled its legacy performance and achieved nearing double-digit EBITDA margins post-integration.
Sugar Free maintains a dominant 96.3% market share, while Everyuth Scrub holds 48.5% of its category.
International business expanded into Poland, Finland, and Portugal through the WeightWorld brand under Comfort Click.
👀 What to Watch
Investors should monitor the company's ability to translate high top-line growth and expanded gross margins into bottom-line profitability as acquisition costs stabilize. The strong market share in core categories provides a defensive moat, but the impact of seasonal brands like Glucon-D and Nycil remains a key variable for upcoming quarters.
